Cellix Bio is a drug discovery and development company that utilizes augmented intelligence and proprietary platform technology, Synergix AI, to accelerate the drug discovery process. Self-described as innovative, it aims to reduce the time and cost of developing new medicines.

Cellix Bio

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Metric
Company Name	Cellix Bio	TransMedics Group, Inc.
Symbol		TMDX
MSH ID	COM:CELLIXBIO	COM:TRANSMEDICS
Market	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare
Industry	Biotechnology	Medical - Devices
Country	US	US
Stage
Employee Count		584
Website	cellixbio.com	transmedics.com
LinkedIn
Founders

Metric
Market Cap		4.56B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue		241.62M
Revenue (LTM)
Revenue (NTM)
Gross Profit		153.99M
EBITDA		8.76M
Operating Income		485K
Net Income		-25.03M
EPS		-0.77
Diluted EPS		-0.77
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.64
Operating Profit Margin		-0.12
EBITDA Margin		0.04
Net Profit Margin		-0.10
Return on Equity		-0.17
Return on Assets		-0.04
Return on Capital Employed		-0.04

CELL

COM:CELLIXBIO

Cellix Bio

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-79.07
P/B Ratio		22.37
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		17.60
EV Multiple		-127.58

Metric
Days Sales Outstanding		115.41
Days Payables Outstanding		72.13
Days Inventory Outstanding		184.46
Operating Cycle		280.50
Cash Conversion Cycle		227.47
Asset Turnover		0.34

Metric
Operating Cash Flow		-13.03M
Free Cash Flow		-192.09M
Cash Flow to Debt		-0.03
Operating Cash Flow/Sales		-0.05
Free Cash Flow Yield		-0.01

Metric
Cash & Equivalents		394.81M
Accounts Receivable		-33.82M
Inventory		44.23M
Goodwill		11.99M
Debt to Capitalization		0.79
Debt to Assets		0.75
Current Ratio		10.93
Quick Ratio		8.34

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.06
R&D to Revenue		0.30
SG&A to Revenue		0.29